Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Patients with CD
≥ 18 to ≤ 75 years-old
Symptomatic CD according to PRO-2 (stool > 3 or abdominal pain score > 1)
Transmural inflammation on baseline MRI (C-score > 0.5 in at least one segment)
Prior exposure to anti-p19 biological therapy
Exposure to more than 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (janus kinase [JAK] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents
Exclude any previous use of p19 IL23s agents
Contra-indication to mirikizumab